Dalteparin LMWH

Acute coronary syndrome

All type of patients:  4 trials  - FRISC (long term) - FRIC (acute phase LMWH vs UFH) - FRIC prolonged treatment phase (LWMH vs PBO) - FRISC (short term)

dalteparin vs placebo (on top of aspirin)

No demonstrated result

suggested myocardial infarction or death by 23% (not demonstrated)

suggested myocardial infarction (fatal and non fatal) by 33% (not demonstrated)

dalteparin vs UFH (on top of aspirin)

No demonstrated result

Acute myocardial infarction

All type of patients:  3 trials  - ASSENT Plus - FRAMI - BIOMACS II

Dalteparin vs placebo

No demonstrated result

Dalteparin vs UFH

No demonstrated result

suggested reinfarction by 74% (not demonstrated)

Percutaneous coronary intervention

All type of patients:  2 trials  - Natarajan (without antiGp2b3a) - Natarajan (+ antiGp2b3a)

dalteparin vs UFH

No demonstrated result

dalteparin vs UFH + anti Gp2b3a

No demonstrated result

Pulmonary embolism

All type of patients:  2 trials  - Kuijer - Meyer

Dalteparin vs unfractionated heparin

No demonstrated result

Thrombosis prevention

Abdominal surgery:  9 trials  - Bergqvist - Onarheim - Koller - Koller - Fricker - Bergqvist - Caen - Hartl - Kakkar

dalteparin vs unfractionated heparin

No demonstrated result

suggested wound haematoma / infection by 48% (not demonstrated)

See more clinical conditions

Elective hip replacement:  9 trials  - Torholm - Eriksson - Matzsch - Matzsch - Haas - Binsack - Barre - Dechavanne - Eriksson

dalteparin vs Dextran

No demonstrated result

dalteparin vs placebo

No demonstrated result

dalteparin vs Unfractionated heparin

No demonstrated result

General surgery:  14 trials  - Ockelford - Bergqvist - Onarheim - Koller - Koller - Fricker - Bergqvist - Caen - Borstad - Briel - Creperio - Hartl - Borstad - Kakkar

dalteparin vs placebo

No demonstrated result

suggested asymptomatic DVT by 74% (not demonstrated)

dalteparin vs unfractionated heparin

No demonstrated result

suggested wound haematoma / infection by 49% (not demonstrated)

Gynaecological surgery:  3 trials  - Borstad - Briel - Borstad

dalteparin vs unfractionated heparin

No demonstrated result

Hip Fracture:  1 trials  - Jorgensen

dalteparin vs placebo

No demonstrated result

Medical patients:  2 trials  - Leizorovicz - PROTECT

dalteparin vs placebo

No demonstrated result

suggested Deep vein thrombosis by 51% (not demonstrated)

suggested asymptomatic DVT by 49% (not demonstrated)

dalteparin vs UFH

No demonstrated result

suggested pulmonary embolism (symptomatic and asymptomatic) by 44% (not demonstrated)

Orthopedic surgery:  14 trials  - Jorgensen - Torholm - Eriksson - Matzsch - Matzsch - Haas - Binsack - Barre - Dechavanne - Eriksson - Monreal - Dahl - Lassen - Hull

dalteparin vs Dextran

No demonstrated result

dalteparin vs placebo

No demonstrated result

dalteparin vs Unfractionated heparin

No demonstrated result

out of hospital Dalteparin vs standard prophylaxis

No demonstrated result

suggested asymptomatic DVT by 59% (not demonstrated)

suggested proximal DVT by 61% (not demonstrated)

Patients with immobilization of the lower extremities:  3 trials  - Lapidus - Lapidus - D-KAf (Selby)

dalteparin vs placebo

No demonstrated result

Patients with myocardial infarction:  1 trials  - Scala

dalteparin vs UFH

No demonstrated result

Venous thrombosis

All type of patients:  8 trials  - Bratt et al - Holm et al - Bratt et al - Lindmarker et al - Holmström - Partsch - Das - Lee

Dalteparin vs unfractionated heparin

No demonstrated result

Dalteparin vs warfarin

No demonstrated result

suggested VTE during active anticoagulant treatment by 42% (not demonstrated)

once daily dalteparin vs twice daily dalteparin

No demonstrated result

See more clinical conditions

Patients with cancer:  1 trials  - CLOT (Lee)

extended dalteparin vs standard treatment

No demonstrated result

suggested Recurrent thromboembolic event by 49% (not demonstrated)